Glizamide S Tablet combines Gliclazide 60mg, a sulfonylurea that stimulates pancreatic insulin secretion, with Sitagliptin 100mg, a DPP-4 inhibitor that enhances incretin activity. This dual mechanism helps achieve optimal glycemic control in type 2 diabetes mellitus by targeting both insulin deficiency and reduced incretin effect.
Clinically, it is indicated for patients with type 2 diabetes who are inadequately controlled on diet, exercise, or monotherapy, providing improved postprandial and fasting blood glucose management. Gliclazide promotes insulin release in response to meals, while Sitagliptin prolongs endogenous incretin hormone activity, supporting stable blood sugar levels.
The tablet formulation ensures accurate dosing, consistent bioavailability, and synergistic antidiabetic effect, making it suitable for diabetes clinics, endocrinology centers, hospitals, and specialty pharmacies. Regular use under medical supervision supports better glycemic control and reduced risk of diabetes-related complications.
Glizamide S Tablet helps in lowering blood glucose levels, maintaining HbA1c within target range, enhancing insulin efficiency, and supporting long-term metabolic health. Its proven dual-action combination makes it a reliable therapy for effective type 2 diabetes management.